The Bold New Player in Cancer: How Chinese Biotechs Are Fueling the Oncology Space
James T. Lee, PhD, Associate Principal, Cello Health BioConsulting, Previoulsy Defined Health
- Brad Loncar, Chief Executive Officer, Loncar Investments LLC
- Guillaume Vignon, PhD, Senior Vice President Business Development, BeiGene
- Weimin Tang, PhD, Global Business Head and Executive VP, I-Mab BioPharma
There are new challenges and opportunities that Chinese Biotech may face as they gain approvals in China and Globally and where they see the future will take them. This being the first year that IO therapeutic deals is now representing less than 50% of oncology deals, while for the first time, Chinese deals with Western companies had the opposite trend of increasing to greater than 50% of oncology deals. This data suggests that Chinese biopharma is propping up the interest in IO, which is a very interesting global power that Chinese biopharma now wield.